Inbal MazorBadichi - Surgical Science VP Marketing
| SUSRF Stock | USD 12.75 0.00 0.00% |
Insider
Inbal MazorBadichi is VP Marketing of Surgical Science Sweden
| Age | 54 |
| Phone | 46 3 17 41 65 60 |
| Web | https://www.surgicalscience.com |
Surgical Science Management Efficiency
The company has return on total asset (ROA) of 0.0212 % which means that it generated a profit of $0.0212 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0357 %, meaning that it generated $0.0357 on every $100 dollars invested by stockholders. Surgical Science's management efficiency ratios could be used to measure how well Surgical Science manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Helge Wei | CompuGroup Medical SE | N/A | |
| Helge Wei | CompuGroup Medical SE | N/A | |
| Yeshua Shainberg | Strainsforpains | 67 | |
| Kenneth Greenwood | Healthcare Integrated Technolog | 65 | |
| Hannes Reichl | CompuGroup Medical SE | 47 | |
| Susan MD | Healthcare Integrated Technolog | 59 | |
| Alexander Weimer | CompuGroup Medical SE | N/A | |
| Angela Teufer | CompuGroup Medical SE | 50 | |
| Eckart Pech | CompuGroup Medical SE | 54 | |
| Claudia Thom | CompuGroup Medical SE | 52 | |
| Claudia Thom | CompuGroup Medical SE | 52 | |
| MBA LLM | CompuGroup Medical SE | 51 | |
| Alexander Weimer | CompuGroup Medical SE | N/A | |
| Jurgen Vollrath | Healthcare Integrated Technolog | N/A | |
| Emanuele Mugnani | CompuGroup Medical SE | 53 | |
| Oliver Bruzek | CompuGroup Medical SE | N/A | |
| Hannes Reichl | CompuGroup Medical SE | 47 | |
| Angela Teufer | CompuGroup Medical SE | 50 | |
| Oliver Bruzek | CompuGroup Medical SE | N/A | |
| Emanuele Mugnani | CompuGroup Medical SE | 53 | |
| Michael Franz | CompuGroup Medical SE | N/A | |
Management Performance
| Return On Equity | 0.0357 | |||
| Return On Asset | 0.0212 |
Surgical Science Sweden Leadership Team
Elected by the shareholders, the Surgical Science's board of directors comprises two types of representatives: Surgical Science inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Surgical. The board's role is to monitor Surgical Science's management team and ensure that shareholders' interests are well served. Surgical Science's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Surgical Science's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Inbal MazorBadichi, VP Marketing | ||
| Ran Bronstein, Pres RD | ||
| Anna Ahlberg, Chief Officer | ||
| Adv, Chief Officer | ||
| Daniel Evestedt, Head Devel | ||
| Jeffrey Berkley, Chief Officer | ||
| Martin Jansson, Head Sales | ||
| Anders Larsson, CoFounder CTO | ||
| Gisli Hennermark, Chief Officer | ||
| Doron Zilberman, VP Sales |
Surgical Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Surgical Science a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0357 | |||
| Return On Asset | 0.0212 | |||
| Profit Margin | 0.18 % | |||
| Current Valuation | 743.09 M | |||
| Shares Outstanding | 50.8 M | |||
| Shares Owned By Insiders | 32.75 % | |||
| Shares Owned By Institutions | 52.03 % | |||
| Price To Earning | 73.41 X | |||
| Price To Book | 2.26 X | |||
| Price To Sales | 15.43 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Surgical Pink Sheet
Surgical Science financial ratios help investors to determine whether Surgical Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Surgical with respect to the benefits of owning Surgical Science security.